At a Glance
- Companies: AMPLY Discovery Ltd; Keeps Biomed (Keeps Biopharma subsidiary)
- Locations: UK (AMPLY); South Korea (Keeps)
- Deal value: Undisclosed investment; strategic co‑development partnership
- Focus area: Oncology therapeutics via AMPLY’s AI‑powered drug discovery
- Next steps: Joint oncology programme development
What happened?
AI drug‑discovery startup AMPLY Discovery announced a strategic investment from South Korea’s Keeps Biomed, a subsidiary of Keeps Biopharma, alongside a co‑development partnership targeting oncology therapeutics. The investment amount remains undisclosed, but it supports AMPLY’s mission to leverage evolution and machine learning for novel medicines.
Why does it matter?
AMPLY’s platform digitises natural protein diversity via next‑gen sequencing, bio‑printing candidates for testing against diseases like cancer. The partnership accelerates AMPLY’s oncology pipeline, combining Keeps’ biopharma expertise with AI to tackle complex targets.
Who’s behind it?
AMPLY, founded in the UK, uses AI to design de novo medicines from evolutionary data, recently raising £1.4m Innovate UK funding. Keeps Biopharma accelerates global new drug pipelines via strategic investments.
How was it achieved?
Keeps provides funding and oncology expertise; AMPLY applies its platform for joint discovery.
What’s next?
Advance co‑developed oncology programmes; expand AMPLY’s AI for broader applications.
What are people saying?
AMPLY CEO Ben Thomas: “Excited for strategic investment… alongside oncology co‑development.”